What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His primary areas of study are Molecular biology, Internal medicine, Cell biology, Endocrinology and Cancer research.
His research integrates issues of Cell culture, Cyclin D1, Cyclin A, Monocyte and Umbilical vein in his study of Molecular biology.
The Internal medicine study combines topics in areas such as Gastroenterology, Fetal hemoglobin and Immunology.
His studies deal with areas such as Regulation of gene expression and Growth factor as well as Cell biology.
His Endocrinology study combines topics in areas such as Endothelial stem cell and Globin.
Douglas V. Faller interconnects Transcription factor, Histone deacetylase, Histone, Cell cycle and CpG site in the investigation of issues within Cancer research.
His most cited work include:
- A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. (2231 citations)
- Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. (622 citations)
- A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders (422 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Molecular biology, Cell biology, Cancer research, Internal medicine and Immunology.
His Molecular biology research is multidisciplinary, incorporating perspectives in Cell culture, Gene expression, Virology, Signal transduction and Globin.
His Globin study integrates concerns from other disciplines, such as Phenylbutyrate, Fetal hemoglobin and Reporter gene.
His Cell biology research incorporates themes from Endothelial stem cell, Jurkat cells, Cell and Growth factor.
His Cancer research research integrates issues from Cell growth, Apoptosis, Cell cycle, Histone deacetylase and Prostate cancer.
Douglas V. Faller combines subjects such as Azacitidine, Endocrinology and Oncology with his study of Internal medicine.
He most often published in these fields:
- Molecular biology (36.39%)
- Cell biology (20.41%)
- Cancer research (21.89%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (16.86%)
- Myelodysplastic syndromes (3.85%)
- Oncology (3.25%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Myelodysplastic syndromes, Oncology, Myeloid leukemia and Azacitidine.
His research in Internal medicine intersects with topics in Gastroenterology and Hypomethylating agent.
His research investigates the connection between Oncology and topics such as AL amyloidosis that intersect with issues in Pharmacotherapy.
His work is dedicated to discovering how Myeloid leukemia, Intensive care medicine are connected with Diabetes mellitus and Eye disease and other disciplines.
In his study, which falls under the umbrella issue of Azacitidine, Myelogenous, Cancer research, Intensive chemotherapy and Endometrial cancer is strongly linked to Phases of clinical research.
His study in the fields of Melanoma under the domain of Cancer research overlaps with other disciplines such as Cytokine release syndrome.
Between 2016 and 2021, his most popular works were:
- Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML (92 citations)
- Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. (26 citations)
- Gut microbiota and salivary diagnostics: the mouth is salivating to tell us something. (24 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
His primary areas of study are Internal medicine, Azacitidine, Myeloid leukemia, Hypomethylating agent and Leukemia.
Internal medicine is often connected to Oncology in his work.
His Azacitidine study combines topics from a wide range of disciplines, such as Chronic myelomonocytic leukemia and Myelodysplastic syndromes.
Douglas V. Faller has included themes like Healthcare utilization, Chemotherapy, Intensive care unit and Emergency medicine in his Myeloid leukemia study.
His work carried out in the field of Hypomethylating agent brings together such families of science as Cytarabine, Randomized controlled trial, Progression-free survival and Retrospective cohort study.
His studies in Myelogenous integrate themes in fields like Cancer research, Confidence interval, Phases of clinical research and Performance status.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
